Zacks Investment Research | Oct 04, 2016 09:29PM ET
It was an eventful week for the biotech sector with companies like Regeneron (NASDAQ:REGN) and Intra-Cellular Therapies (NASDAQ:ITCI) presenting data while Summit (NASDAQ:SMMT) shot up on a collaboration agreement with Sarepta (NASDAQ:SRPT) .
Recap of the Week’s Most Important Stories
Summit Shoots Up on Sarepta Collaboration: Summit’s shares shot up 65.9% on the company’s deal with Sarepta granting rights to its utrophin modulator pipeline in Europe, Turkey and the Commonwealth of Independent States for the treatment of Duchenne muscular dystrophy (DMD). The companies will collaborate for the development of novel treatments for DMD. In addition to receiving an upfront payment of $40 million, Summit is entitled to receive up to $522 million on the achievement of ezutromid-related milestones plus escalating royalties. The companies will share R&D costs. Ezutromid is the lead candidate in Summit’s pipeline. Summit’s utrophin modulation technology has the potential to lead to the development of disease-modifying treatments for all DMD patients, regardless of their underlying dystrophin gene mutation.
Summit is a Zacks Rank #2 (Buy) stock. You can see Amgen (NASDAQ:AMGN)'s Kyprolis Disappoints, Array Up on Cancer Data ).
What's Next in the Biotech World?
Watch out for the usual pipeline and regulatory updates from biotech companies.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.